JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Guardant Health Inc

Geschlossen

BrancheGesundheitswesen

69.22 1.87

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

66.58

Max

69.22

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.7M

-100M

Verkäufe

29M

232M

Gewinnspanne

-43.044

Angestellte

1,999

EBITDA

22M

-89M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+5.6% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

3.3B

8.8B

Vorheriger Eröffnungskurs

67.35

Vorheriger Schlusskurs

69.22

Nachrichtenstimmung

By Acuity

21%

79%

45 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Okt. 2025, 20:49 UTC

Ergebnisse

Correction to Thermo Fisher Article on Oct. 22

23. Okt. 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23. Okt. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. Okt. 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23. Okt. 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23. Okt. 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23. Okt. 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23. Okt. 2025, 22:49 UTC

Akquisitionen, Fusionen, Übernahmen

How Trump Sparked a New Era of State Capitalism -2-

23. Okt. 2025, 22:49 UTC

Akquisitionen, Fusionen, Übernahmen

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23. Okt. 2025, 22:17 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23. Okt. 2025, 21:41 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23. Okt. 2025, 21:05 UTC

Ergebnisse

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23. Okt. 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

23. Okt. 2025, 20:50 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

23. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. Okt. 2025, 20:35 UTC

Ergebnisse

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23. Okt. 2025, 20:28 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23. Okt. 2025, 20:15 UTC

Market Talk
Ergebnisse

Global Commodities Roundup: Market Talk

23. Okt. 2025, 20:10 UTC

Ergebnisse

Newmont Mining 3Q Adj EPS $1.71

23. Okt. 2025, 20:10 UTC

Ergebnisse

Newmont Mining 3Q Sales $5.52B

23. Okt. 2025, 20:10 UTC

Ergebnisse

Newmont Mining 3Q EPS $1.67

23. Okt. 2025, 20:09 UTC

Ergebnisse

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23. Okt. 2025, 20:07 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

23. Okt. 2025, 20:07 UTC

Market Talk
Ergebnisse

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23. Okt. 2025, 20:07 UTC

Ergebnisse

Blackstone Looks to IPOs for Investment Exits -- Update

23. Okt. 2025, 20:05 UTC

Ergebnisse

Intel 3Q Gross Margin 38.2% >INTC

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel: 4Q Guidance Excludes Altera >INTC

23. Okt. 2025, 20:04 UTC

Ergebnisse

Intel Sees 4Q Adj EPS 8c >INTC

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

5.6% Vorteil

12-Monats-Prognose

Durchschnitt 71.84 USD  5.6%

Hoch 90 USD

Tief 60 USD

Basierend auf 21 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

21 ratings

21

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

38.86 / 47.41Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

45 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat